Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.
C RyanL GuentherP FoleyJ WeismanR T BurgeG GalloK SeeM McKean-MatthewsC C BertramJoseph Frank MerolaPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)